formally known as gpha

Same medicine. Same results.
Lower cost.

Biosimilars Council Announces 2016 Board of Directors

Contact: Steve Arnoff 202.249.7113

ORLANDO (Feb. 23, 2016) — The Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA), today announced its 2016 Board of Directors. Dr. Bertrand C. Liang, Chief Executive Officer, Pfenex Inc has been re-elected as Biosimilars Council Chairman. The Council also named Bruce Leicher, Senior Vice President and General Counsel, Momenta Pharmaceuticals, Vice Chairman and Bruce Lott, Mylan’s vice president of State Government Relations and Global Biologics Policy, as Secretary/Treasurer.

“I am very pleased to continue chairing the Biosimilars Council and working to ensure a competitive legal and policy framework for biosimilars, and interchangeable biologics, in the United States,” said Dr. Liang. “As the leading manufacturer voice for these life-changing medicines, the Council plays an important role in educating payors, providers, and policy makers on the safety and efficacy of biosimilars, while encouraging a pathway that expedites patient access.”

Biologics are medicines made from living organisms, and they are used to treat diseases such as cancer, AIDS, heart disease, rheumatoid arthritis, multiple sclerosis and diabetes. Once FDA-approved, there are no clinically meaningful differences between the biosimilar and the reference (brand) biologic in terms of safety, purity and potency.

“The Biosimilars Council is a strong partner for those involved with this rapidly expanding industry. With Bert’s continued leadership, the Council will continue to be instrumental in discussions on biosimilar naming, reimbursement, state substitution and other policy and regulatory priorities that enhance patient access to more affordable medicines,” said Chip Davis, President and CEO, GPhA.

“Projected savings from biosimilars vary from $44 billion to more than $250 billion over 10 years, but that potential hinges on the creation of an environment that encourages pharmaceutical competition,” said Leicher. “The Council is right on the front lines of this effort and will continue to encourage policy that exerts downward cost pressure on our health system.”

“I’m very pleased to be a part of the Biosimilars Council representing manufacturers of more affordable therapies for patients managing many chronic and severe diseases,” said Lott. “The U.S. introduction of more biosimilars will lower treatment costs and provide patients with safe and effective choices that can translate to billions in savings for the health system.”

The Biosimilars Council Board of Directors includes representatives from the following member companies:
Accord Healthcare • Amneal BioSciences, LLC • ApoBiologix • Biocon • Dr. Reddy’s • Momenta Pharmaceuticals, Inc. • Mylan Inc. • Pfenex Inc. • Sandoz • Sun Pharmaceutical Industries Ltd. • Teva Pharmaceuticals USA • Zydus Pharmaceuticals

About the GPhA Biosimilars Council
The Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.

About GPhA
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 88 percent of the prescriptions dispensed in the U.S. but consume just 28 percent of the total drug spending. Additional information is available at gphaonline.org. Follow us on twitter: @gpha.